

Aligos Therapeutics stock rose in after-hours trading after a $25 million licensing payment and China Breakthrough Therapy designation.
You can purchase shares of Aligos Therapeutics (NASDAQ:ALGS) through any online brokerage.
Other companies in Aligos Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Aligos Therapeutics has a consensus price target of $43.00.
The stock price for Aligos Therapeutics (NASDAQ: ALGS) is $4.7251 last updated November 3, 2026 at 6:22 PM EST.
There are no upcoming dividends for Aligos Therapeutics.
Aligos Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Aligos Therapeutics.
Aligos Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic...